The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study

Inclusion Criteria: * Diagnosed with HCC according to the European Association for the Study of the Liver (EASL) diagnostic criteria * TACE failure/refractoriness by Liver Cancer Study Group of Japan (LCSGJ) criteria * Without extrahepatic metastasis * The following laboratory parameters: Platelet count ≥ 60,000/μL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 1.5 mg/dL Serum albumin ≥ 35 g/L ASL and AST ≤ 5 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) \>1,500/mm3 Exclusion Criteria: * Known history of HIV * History of organ allograft * Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry. * Serious non-healing wound, ulcer, or bone fracture * Evidence of bleeding diathesis. * Any other hemorrhage/bleeding event \> CTCAE Grade 3 within 4 weeks of first dose of study drug